257 related articles for article (PubMed ID: 25794535)
21. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
[TBL] [Abstract][Full Text] [Related]
22. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
[TBL] [Abstract][Full Text] [Related]
24. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors.
Yim H
Anticancer Drugs; 2013 Nov; 24(10):999-1006. PubMed ID: 23949254
[TBL] [Abstract][Full Text] [Related]
25. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
Gray JE; Infante JR; Brail LH; Simon GR; Cooksey JF; Jones SF; Farrington DL; Yeo A; Jackson KA; Chow KH; Zamek-Gliszczynski MJ; Burris HA
Invest New Drugs; 2015 Dec; 33(6):1187-96. PubMed ID: 26403509
[TBL] [Abstract][Full Text] [Related]
26. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Bahleda R; Sessa C; Del Conte G; Gianni L; Capri G; Varga A; Oprea C; Daglish B; Hospitel M; Soria JC
Invest New Drugs; 2014 Dec; 32(6):1188-96. PubMed ID: 24898305
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
Levy AS; Meyers PA; Wexler LH; Jakacki R; Angiolillo A; Ringuette SN; Cohen MB; Gorlick R
Cancer; 2009 Jan; 115(1):207-16. PubMed ID: 19090012
[TBL] [Abstract][Full Text] [Related]
29. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
Forster M; Kaye S; Oza A; Sklenar I; Johri A; Cheung W; Zaknoen S; Gore M
Clin Cancer Res; 2007 Jul; 13(14):4178-84. PubMed ID: 17634546
[TBL] [Abstract][Full Text] [Related]
30. Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
Wu CP; Hsieh CH; Hsiao SH; Luo SY; Su CY; Li YQ; Huang YH; Huang CW; Hsu SC
Mol Pharm; 2015 Nov; 12(11):3885-95. PubMed ID: 26412161
[TBL] [Abstract][Full Text] [Related]
31. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Lara PN; Mack PC; Synold T; Frankel P; Longmate J; Gumerlock PH; Doroshow JH; Gandara DR
Clin Cancer Res; 2005 Jun; 11(12):4444-50. PubMed ID: 15958629
[TBL] [Abstract][Full Text] [Related]
32. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD
World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654
[TBL] [Abstract][Full Text] [Related]
33. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
34. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
Müller-Tidow C; Bug G; Lübbert M; Krämer A; Krauter J; Valent P; Nachbaur D; Berdel WE; Ottmann OG; Fritsch H; Munzert G; Garin-Chesa P; Fleischer F; Taube T; Döhner H
Br J Haematol; 2013 Oct; 163(2):214-22. PubMed ID: 24033250
[TBL] [Abstract][Full Text] [Related]
35. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).
Wäsch R; Hasskarl J; Schnerch D; Lübbert M
Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
37. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
[TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
